Mereo BioPharma Group Q3 2026 Results: Net Loss of $5.86M, Loss Narrows
Mereo BioPharma reported a net loss of $19.6 million for the nine months ended September 30, 2026, an improvement from the $34.5 million loss in the prior year period. Cash and cash equivalents decreased to $26.1 million from $41.0 million at the end of 2025, primarily driven by research and development expenses for its rare disease clinical programs.
- Key figure
- Net loss $5.86M